Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Businessweek Archives

Table: Mapping The Genome Companies


Cover Story

TABLE: Mapping the Genome Companies

Pharmaceutical giants and biotech startups are mining the treasures in the

human genome. Some key players:

COMPANY STRATEGY

HUMAN GENOME Sequencing almost all human genes, then hopes to

SCIENCES develop drugs and diagnostics, mostly with partners.

SMITHKLINE Invested $125 million in HGS to use its sequences to

BEECHAM create new products.

INCYTE Sequencing cDNA from many different tissues to find

PHARMACEUTICAL interesting genes. Is selling access to its data.

PFIZER Paid InCyte $25 million for access to database.

UPJOHN Signed $20 million deal with InCyte for gene data.

BRISTOL-MYERS Invested in SEQ and Cadus to develop new

SQUIBB sequencing technology and drug screens.

MILLENNIUM Searching for specific genes that cause obesity,

diabetes, asthma, atherosclerosis, and cancer.

HOFFMANN- Signed $70 million deal with Millennium.

LAROCHE

MERCK Paid Washington University to sequence

200,000 gene fragments. Makes data public.

SEQUANA Searches family histories and HMO data for genes

THERAPEUTICS that cause hypertension, asthma, and obesity.

AMGEN Sequencing genes to find new drug targets.

TAKEDA Uses SmithKline and HGS data to develop drugs.

DATA: BUSINESS WEEK


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus